CRISPR Therapies, Base Editing and Approvals — 2026-09-21
This week's gene-editing news is dominated by investor momentum around CRISPR Therapeutics as year-end catalysts firm up, plus fresh analysis of what Casgevy actually costs payers. A Chinese-language deep dive examines Intellia's lonvo-z, whose FDA priority review sets up the world's first in-vivo CRISPR approval decision in March 2027.
CRISPR Therapies, Base Editing and Approvals — 2026-09-21
Top developments
CRISPR Therapeutics back in the spotlight with near-term catalysts
CRISPR Therapeutics (Nasdaq: CRSP) heads into the Morgan Stanley 24th Annual Global Healthcare Conference on 14 September 2026 with a pipeline spanning hemoglobinopathies, CAR T therapies and type 1 diabetes, and the stock has drawn fresh investor attention over the past week. The Motley Fool argues on 20 September that the stock is "still a buy" after a rocky 2026, citing near-term catalysts firming up. A separate 17 September analysis takes a ten-year view, noting the company has a medicine on the market and a broad pipeline, though the ride may not be smooth.
Casgevy revenue momentum noted in Chinese-language coverage
Chinese crypto/finance outlet Bitget reports that on 17 September CRISPR Therapeutics shares rose sharply, attributing the move to "CASGEVY volume growth + pipeline catalysts + gene editing." Management on 14 September highlighted continued Casgevy commercialization momentum, with Vertex disclosing latest quarterly revenues for the approved gene-edited medicine. The move matters because exa-cel commercial uptake is the key revenue proof-point for the ex-vivo CRISPR category.
Intellia's lonvo-z: world's first in-vivo CRISPR approval within reach
Chinese gene-therapy blog PackGene published (11 September) a detailed analysis of the FDA's acceptance of Intellia's BLA for lonvo-z (lonvoguran ziclumeran) with priority review and a target action date of 10 March 2027. If approved, it would become the world's first marketed in-vivo CRISPR gene-editing therapy — a milestone that will shape regulatory expectations for Verve's cholesterol programs and other LNP-delivered editors.
What the $2.2M Casgevy sticker actually covers
While the list price of Casgevy is $2.2 million (Lyfgenia: $3.1 million), a 2026 RxInsider breakdown calculates total cost of care closer to $3 million per patient, with Medicaid bearing most of it. By 2026, 33 states plus DC and Puerto Rico — roughly 84% of the Medicaid sickle cell disease population — had joined the CMS CGT Access Model, under which CMS negotiates outcomes-based agreements with Vertex and bluebird on behalf of state Medicaid programs, the first federal multi-state outcomes deal for any drug.
Local view
Chinese biotech commentary is focused on Intellia's lonvo-z priority review and its implications for domestic in-vivo editing developers. PackGene frames the 10 March 2027 PDUFA date as a potential first-ever in-vivo CRISPR approval globally. Chinese-language analysis of base/precision editing as "CRISPR 2.0" notes no products are approved yet but multiple pipelines are in mid-to-late clinical stages, with commercialization expected within 3–5 years. Separately, Chinese-language outlets continue to cover the July Science/Retraction Watch investigation into a concealed death in a first-in-human brain base-editing experiment at Xinhua Hospital in Shanghai involving a six-year-old girl — a story relevant to China gene-therapy oversight.
Context & numbers
- Casgevy list price: $2.2 million; Lyfgenia: $3.1 million; full cost of care for Casgevy estimated near $3 million
- 33 states + DC + Puerto Rico in the CMS CGT Access Model, covering ~84% of Medicaid's SCD population
- Lonvo-z BLA target action date: 10 March 2027 (FDA priority review)
- Lilly's VERVE-102 has treated 35 patients; Phase 2 expected by end of 2026, per a July 2026 landscape review
On the radar
- Morgan Stanley Global Healthcare Conference (began 14 September 2026): any CRISPR Therapeutics pipeline updates from the event
- Lonvo-z FDA decision (10 March 2027) — the pivotal in-vivo CRISPR approval test
- Q3 drug-approval window: between early August and end of September the FDA faces target action dates across oncology, gene therapy and rare disease — watch for gene-editing-related actions in the closing weeks -– Verve's VERVE-102 Phase 2 entry expected by end of 2026
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
